NervGen Pharma CorpNGEN
Price$1.76

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Free Cash Flow -$14.2MTTM through 31 Dec 2025

Margins

Current

Returns

-190.1%ROA

Balance Sheet Health

Current Ratio1.16x
Cash & Equivalents$22.1M

Quality Metrics

Piotroski F-Score2 / 9
Earnings-Beat Rate0.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Research and development of pharmaceutical drugs$0
View details

Initiation of the RESTORE Phase 3 registrational study in chronic tetraplegia planned for mid-2026.

Financials converted at 1.3695 from CAD.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.